Novo Nordisk Has Plans For Semaglutide In NASH Too

 
• By Joseph Haas

With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.

novo nordisk
Novo Nordisk's plans in NASH include semaglutide and several other candidates/combos • Source: Shutterstock: Tada Images

More from Strategy

More from Business